文献速递物质与行为成瘾

G蛋白偏向性μ阿片受体激动剂TRV130在大鼠模型中减少羟考酮寻求与复吸

In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia.
PubMed 文献 · Biol Psychiatry · 2020-02-24

研究在大鼠羟考酮自我给药模型中模拟维持治疗,比较丁丙诺啡与G蛋白偏向性μ阿片受体激动剂TRV130对戒断期羟考酮寻求和复吸的影响。结果显示两药减少消退反应和复吸获得,TRV130还预防羟考酮所致脑缺氧,效果部分存在性别差异。

要点

  • TRV130和丁丙诺啡减少雄性大鼠消退反应和复吸获得,对情境诱发复吸效果较弱。
  • 雌性大鼠中丁丙诺啡减少全部三项测试反应,TRV130仅减少消退反应。
  • 两性中TRV130均预防中剂量羟考酮所致急性脑缺氧。

核心结论

  • TRV130以部分性别特异方式减少戒断期羟考酮寻求和摄取,并预防羟考酮诱导的急性脑缺氧。
  • G蛋白偏向性μ阿片受体激动剂应考虑作为阿片类成瘾的复吸预防维持治疗。

研究设计与样本

  • 大鼠自我给药羟考酮(6小时/天,14天)后植入渗透泵给予丁丙诺啡或TRV130(0、3、6或9 mg/kg/day)。
  • 进行三项连续测试:消退反应、情境诱发复吸和复吸获得,并检测伏隔核氧水平。

主要发现

  • 雄性大鼠中丁丙诺啡和TRV130减少消退反应和复吸获得,对情境诱发复吸效果较弱(不显著)。
  • 雌性大鼠中丁丙诺啡减少全部三项测试反应,TRV130仅减少消退反应。
  • 两性中TRV130均预防中剂量羟考酮所致急性脑缺氧。

关键数值与推荐

  • TRV130剂量为0、3、6或9 mg/kg/day。
  • 羟考酮自我给药为6小时/天,持续14天。

临床怎么用

  • 提示G蛋白偏向性μ阿片受体激动剂可能作为阿片类成瘾复吸预防的维持治疗候选。
  • 临床转化前需进一步验证性别差异及对情境诱发复吸的较弱效果。

局限性

  • 为动物模型研究,结果不能直接外推至人类。
  • 对情境诱发复吸的效果在雄性中不显著,雌性中TRV130仅减少消退反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Maintenance treatment with opioid agonists (buprenorphine, methadone) is effective for opioid addiction but does not eliminate opioid use in all patients. We modeled maintenance treatment in rats that self-administered the prescription opioid oxycodone. The maintenance medication was either buprenorphine or the G protein-biased mu opioid receptor agonist TRV130. We then tested prevention of oxycodone seeking and taking during abstinence using a modified context-induced reinstatement procedure, a rat relapse model. METHODS: We trained rats to self-administer oxycodone (6 hours/day, 14 days) in context A; infusions were paired with discrete tone-light cues. We then implanted osmotic pumps containing buprenorphine or TRV130 (0, 3, 6, or 9 mg/kg/day) and performed 3 consecutive tests: lever pressing reinforced by oxycodone-associated discrete cues in nondrug context B (extinction responding), context-induced reinstatement of oxycodone seeking in context A, and reacquisition of oxycodone self-administration in context A. We also tested whether TRV130 maintenance would protect against acute oxycodone-induced decreases in nucleus accumbens oxygen levels. RESULTS: In male rats, buprenorphine and TRV130 decreased extinction responding and reacquisition of oxycodone self-administration but had a weaker (nonsignificant) effect on context-induced reinstatement. In female rats, buprenorphine decreased responding in all 3 tests, while TRV130 decreased only extinction responding. In both sexes, TRV130 prevented acute brain hypoxia induced by moderate doses of oxycodone. CONCLUSIONS: TRV130 decreased oxycodone seeking and taking during abstinence in a partly sex-specific manner and prevented acute oxycodone-induced brain hypoxia. We propose that G protein-biased mu opioid receptor agonists, currently in development as analgesics, should be considered as relapse prevention maintenance treatment for opioid addiction.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bossert JM, Kiyatkin EA, Korah H, et al. In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia. Biol Psychiatry. 2020. PMID: 32305216. doi:10.1016/j.biopsych.2020.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。